A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), alcohol use disorder (“AUD”) and alcohol-associated liver disease (“ALD”). We may also pursue additional indications for pemvidutide that leverage its differentiated clinical profile. Except where the context indicates otherwise, references to “we,” “us,” “our,” “Altimmune”, or the “Company” refer to the company and its subsidiaries. We obtained pemvidutide as part of the acquisition Spitfire Pharma Inc., in July of 2019. Pemvidutide was designed as a MASH therapeutic based on the understanding that targeting both metabolic and liver-specific effects could lead to an improved and differentiated candidate.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -88M | -88M | -95M | -88M | -85M | -97M |
| EPS | $-1.00 | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Free Cash Flow | -68M | -68M | -80M | -76M | -63M | -90M |
| ROIC | -34.7% | -46.0% | -77.0% | -45.6% | -44.6% | -48.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.15 | 0.15 | 0.13 | 0.09 | 0.02 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -94M | -94M | -103M | -96M | -88M | -97M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -39.2% | -50.6% | -77.0% | -45.6% | -45.7% | -48.8% |
| Shares Outstanding | 88M | 88M | 71M | 53M | 47M | 41M |
Altimmune, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Altimmune, Inc. (ALT) has a 5-year average return on invested capital (ROIC) of -52.3%. This is below average and may indicate limited pricing power.
Altimmune, Inc. (ALT) has a market capitalization of $290M. It is classified as a small-cap stock.
Altimmune, Inc. (ALT) does not currently pay a regular dividend.
Altimmune, Inc. (ALT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Altimmune, Inc. (ALT) generated $-68 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Altimmune, Inc. (ALT) has a debt-to-equity ratio of 0.15. This indicates a conservatively financed balance sheet.
Altimmune, Inc. (ALT) reported earnings per share (EPS) of $-1.00 in its most recent fiscal year.
Altimmune, Inc. (ALT) has a return on equity (ROE) of -50.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for Altimmune, Inc. (ALT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Altimmune, Inc. (ALT) has a book value per share of $2.55, based on its most recent annual SEC filing.